Mirakhor Samani S, Ghasemi H, Rezaei Bookani K, Shokouhi B
Qazvin University of Medical Sciences, Department of Pathology, Qazvin, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Internal Medicine, Tabriz, Iran.
Acta Endocrinol (Buchar). 2019 Jan-Mar;-5(1):69-73. doi: 10.4183/aeb.2019.69.
Nesfatin-1 is a novel peptide with both central and peripheral anorexigenic regulatory properties. Besides its effects on food intake, few studies have suggested a possible role for this peptide in the pathogenesis of diabetes mellitus type 2.
To compare serum levels of nesfatin-1 between healthy, normal-weight persons and three groups including healthy underweight, healthy obese and diabetic subjects.
Prospective, case-control study, performed between January 2015 and January 2016.
Fasting levels in serum nesfatin-1 were measured in 30 healthy, normal-weight individuals (controls), 30 healthy underweight persons, 30 healthy obese persons, and 30 patients with newly diagnosed diabetes type 2 using standard enzyme-linked immunosorbent assay (ELISA) kits.
The mean serum nesfatin-1 level was significantly higher in controls (2.61 ng/mL) compared to that in obese (1.13 ng/mL) and diabetic (0.99 ng/mL) patients; and significantly lower than that in the underweight group (3.50 ng/mL). The obese and diabetic groups were comparable in this regard. No significant association was found between serum nesfatin-1 level and age, sex, or body mass index.
Serum nesfatin-1 is possibly associated with weight-related abnormalities in otherwise healthy subjects and diabetes type 2. Obesity and diabetes type 2 may share a common pathologic point in this regard.
Nesfatin-1是一种新型肽，具有中枢和外周厌食调节特性。除了对食物摄入的影响外，很少有研究表明这种肽在2型糖尿病发病机制中可能发挥作用。
比较健康、体重正常者与包括健康体重过轻、健康肥胖及糖尿病患者在内的三组人群的血清Nesfatin-1水平。
2015年1月至2016年1月进行的前瞻性病例对照研究。
使用标准酶联免疫吸附测定（ELISA）试剂盒，对30名健康、体重正常个体（对照组）、30名健康体重过轻个体、30名健康肥胖个体及30名新诊断的2型糖尿病患者测定血清Nesfatin-1的空腹水平。
与肥胖（1.13 ng/mL）和糖尿病（0.99 ng/mL）患者相比，对照组血清Nesfatin-1平均水平显著更高（2.61 ng/mL）；且显著低于体重过轻组（3.50 ng/mL）。肥胖组和糖尿病组在这方面具有可比性。血清Nesfatin-1水平与年龄、性别或体重指数之间未发现显著关联。
血清Nesfatin-1可能与健康个体的体重相关异常及2型糖尿病有关。肥胖和2型糖尿病在这方面可能存在共同的病理点。
